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December 2017
Drug Name: Erenumab
Manufacturer: Amgen
Indication: Prevention of migraine
Formulation: Subcutaneous injection
BLA
Drug Name: Binimetinib/encorafenib
Manufacturer: Array BioPharma
Indication: BRAF-mutant melanoma
Formulation: Oral tablet/capsule
Erenumab is a monoclonal antibody targeting 
the calcitonin gene-related peptide (CGRP) receptor. 
Erenumab is being studied for the prevention of 
migraine in patients with at least four migraine days 
per month. 
The Phase III STRIVE (N=955) and ARISE (N=577) 
trials evaluated the safety and efficacy of once-
monthly treatment with erenumab compared to 
placebo in adult patients with a minimum of a 
one-year history of episodic migraines. In STRIVE, 
patients in the erenumab 70 mg and 140 mg groups 
experienced 3.2-day and 3.7-day reductions in 
monthly migraine days (MMDs), respectively, from 
baseline to weeks 13 to 24 compared to a 1.8-day 
reduction in the placebo group (P<0.001 for both). 
In addition, 43.3 percent of patients in the 70 mg 
group and 50.0 percent of patients in the 140 mg 
group experienced a 50 percent or greater reduction 
in MMDs compared to 27 percent of patients in 
the placebo group (odds ratio [OR] 2.13 and 2.81, 
respectively). In ARISE, patients in the erenumab 70 
mg group experienced a 2.9-day reduction in MMDs 
compared to a 1.8-day reduction in the placebo 
group (P<0.001). In both trials, the frequency of 
adverse events was similar between all treatment 
groups. 
If approved, erenumab would be the first 
monoclonal antibody targeting the CGRP receptor 
and may offer a treatment alternative for the 
prevention of migraines. The Biologics License 
Application (BLA) for erenumab has been accepted 
for review by the FDA and a decision is expected by 
May 17, 2018.
Promising  
New Agents
Patisiran
Rolling NDA 
submission initiated 
in November 2017
Tezacaftor/ivacaftor
FDA decision 
expected  
Feb. 28, 2018
Projected        
Generic Entry 
Enbrel®
Lyrica®
Remodulin®
Sensipar®
Investigational 
Indications
Canakinumab
For the prophylaxis 
of major adverse 
cardiovascular 
events
Obeticholic acid
For the treatment 
of non-alcoholic 
steatohepatitis 
FDA Updates
Baricitinib
Manufacturer 
received complete 
response letter
Dexamethasone 
insert
Manufacturer 
received complete 
response letter
Romosozumab
Manufacturer 
received complete 
response letter
Binimetinib, a MEK inhibitor, and encorafenib, 
a BRAF inhibitor, affect key protein kinases in the 
cellular signaling pathway. The combination is being 
investigated for the treatment of BRAF-mutant 
advanced, unresectable, or metastatic melanoma.
The two-part, randomized, open-label Phase 
III COLUMBUS trial (N=921) compared binimetinib 
plus encorafenib to monotherapy with vemurafenib 
or encorafenib. In Part 1 (N=577), the median 
progression-free survival (mPFS) was 14.9 months in 
patients treated with binimetinib 45 mg twice daily 
plus encorafenib 450 mg once daily compared to 7.3 
months in patients treated with vemurafenib 960 mg 
twice daily (hazard ratio [HR] 0.54, 95 percent CI 
0.41 to 0.71, P<0.001) and 9.6 months in patients 
treated with encorafenib 300 mg once daily (HR 
0.75, 95 percent CI 0.56 to 1.00, P=0.051). In Part 
2 (N=344), the mPFS was 12.9 months in patients 
treated with binimetinib 45 mg twice daily plus 
encorafenib 300 mg once daily compared to 9.2 
months in patients treated with encorafenib 300 mg 
once daily (HR 0.77, 95 percent CI 0.61 to 0.97). 
If approved, binimetinib plus encorafenib may 
provide an effective treatment option for BRAF-
mutant advanced, unresectable, or metastatic 
melanoma. These agents are also being investigated 
in Phase II trials for the treatment of relapsed or 
refractory multiple myeloma and BRAF V600E-
mutant colorectal cancer. New Drug Applications 
(NDAs) for binimetinib and encorafenib have 
been accepted for review by the Food and Drug 
Administration (FDA) and a decision is expected by 
June 30, 2018.
NDA
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Promising New Agents
Non-Specialty Specialty
Drug Name: Lanadelumab
Manufacturer: Shire
Indication: Hereditary angioedema     
Formulation: Subcutaneous injection
NDA
Drug Name: Lasmiditan
Manufacturer: Eli Lilly
Indication: Migraine
Formulation: Oral tablet
Drug Name: Omadacycline 
Manufacturer: Paratek
Indication: ABSSSI, CABP
Formulation: Oral, intravenous
Phase III
Lanadelumab is being investigated for 
the long-term prophylaxis of angioedema 
attacks in patients with hereditary 
angioedema (HAE). Lanadelumab is a long-
acting, fully-human monoclonal antibody 
that binds to plasma kallikrein.
The efficacy and safety of 
lanadelumab was evaluated in the Phase 
III HELPTM study (N=125). Patients ages 12 
years and older with type I and II HAE were 
randomized to one of three lanadelumab 
regimens (300 mg every two weeks, 300 
mg every four weeks, or 150 mg every four 
weeks) or placebo. The primary efficacy 
endpoint, the number of investigator-
confirmed angioedema attacks during the 
26-week treatment period, was reduced by 
87 percent in the 300 mg every two weeks 
group, 73 percent in the 300 mg every 
four weeks group, and 76 percent in the 
150 mg every four weeks group compared 
to placebo (P<0.001). Results were found 
to be similar regardless of baseline attack 
frequency. Lanadelumab was generally 
well-tolerated with the most commonly-
reported adverse event being injection site 
pain. The HELPTM Study Extension is ongoing 
to evaluate long-term safety.
If approved, lanadelumab may provide 
an advantage over currently-available long-
term HAE prophylactic medications due 
to less frequent dosing and convenience 
of administration. A BLA for lanadelumab 
is anticipated by late 2017 or early 2018. 
The FDA has granted lanadelumab the 
Orphan Drug and Breakthrough Therapy 
designations.
Omadacycline is a first-in-class 
aminomethylcycline with broad-spectrum 
activity against gram-positive, gram-
negative, and atypical bacteria. It is 
being studied for the treatment of acute 
bacterial skin and skin structure infection 
(ABSSSI) and community-acquired bacterial 
pneumonia (CABP).
In the Phase III OPTIC trial (N=774), 
adults with CABP were randomized to 
omadacycline or moxifloxacin for 7 to 
14 days. Clinically stable patients in 
both treatment arms transitioned to 
omadacycline 300 mg or moxifloxacin  
400 mg orally once daily after a minimum 
of three days of intravenous therapy. The 
primary endpoint of non-inferiority to 
moxifloxacin at the early clinical response 
(ECR) was defined as an improvement 
in ≥2 of 4 symptoms at 72 to 120 hours. 
Treatment with omadacycline was non-
inferior to moxifloxacin, with 81.1 and 82.7 
percent of patients, respectively, achieving 
an ECR (treatment difference -1.6,  
95 percent CI -7.1 to 3.8). In the Phase 
III OASIS-1 (N=645) and OASIS-2 (N=735) 
trials of adults with ABSSSI, treatment 
with omadacycline was non-inferior 
to linezolid at the ECR, defined as ≥20 
percent reduction in lesion size at  
48 to 72 hours post-first dose.
Omadacycline received the Qualified 
Infectious Disease Product and Fast Track 
designations from the FDA and may offer 
a treatment option for patients with 
ABSSSI or CABP who are not candidates 
for standard antibiotic therapy. 
Omadacycline is also being studied for 
the treatment of uncomplicated urinary 
tract infection. NDA submissions are 
anticipated in early 2018.
Lasmiditan is a first-in-class serotonin 
(5HT)1F agonist targeting receptors in the 
trigeminal pathway. It is being investigated 
for the acute treatment of migraine.
In the randomized, double-blind, 
placebo-controlled Phase III SPARTAN 
trial (N=3,007), the safety and efficacy 
of three lasmiditan doses were compared 
to placebo for the acute treatment of 
migraine. At two hours post-first dose, 
the percentage of patients who were 
migraine pain-free was greater in the 
lasmiditan 50 mg, 100 mg, and 200 mg 
groups compared to the placebo group (28.6 
percent, P=0.003; 31.4 percent, P<0.001; 
38.8 percent, P<0.001; and 21.3 percent, 
respectively). More patients treated with 
lasmiditan 50 mg, 100 mg, and 200 mg were 
also free of their migraine-associated most 
bothersome symptom at two hours post-
first dose compared to patients treated 
with placebo (40.8 percent, P=0.009; 44.2 
percent, P<0.001; 48.7 percent, P<0.001; 
and 33.5 percent, respectively). These 
findings were consistent with the previous 
Phase III trial, SAMURAI (N=2,232), which 
compared two doses of lasmiditan  
(100 mg and 200 mg) to placebo. The 
ongoing, open-label Phase III GLADIATOR 
study will evaluate the long-term safety of 
lasmiditan.
If approved, lasmiditan may provide a 
therapeutic alternative for the treatment 
of migraine without the vasoconstrictor 
activity associated with 5HT1B/1D receptor 
agonists, such as triptans. An NDA 
submission for lasmiditan is anticipated in 
the second half of 2018.
Phase III
Phase III
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Drug Name: Tezacaftor/ivacaftor
Manufacturer: Vertex
Indication: Cystic fibrosis
Formulation: Oral tablet
NDA
Drug Name: Patisiran
Manufacturer: Alnylam
Indication: hATTR amyloidosis
Formulation: Intravenous infusion
Drug Name: Ozanimod
Manufacturer: Celgene
Indication: Relapsing MS                                           
Formulation: Oral capsule
Phase III
Tezacaftor/ivacaftor is a combination 
product that includes an FDA-approved 
cystic fibrosis (CF) transmembrane 
conductance regulator (CFTR) potentiator, 
ivacaftor, and an investigational CFTR 
corrector, tezacaftor. Tezacaftor/ivacaftor 
is being studied for the treatment of 
patients ages 12 and older with CF and 
two copies of the F508del mutation or 
one copy of the F508del mutation and one 
residual function mutation. 
The Phase III EVOLVE trial (N=477) 
compared tezacaftor 100 mg once daily in 
combination with ivacaftor 150 mg twice 
daily to placebo in patients with two copies 
of the F508del mutation. Treatment with 
tezacaftor/ivacaftor resulted in a mean 
absolute improvement in percent predicted 
forced expiratory volume in one second 
(ppFEV1) of 4.0 percentage points from 
baseline to 24 weeks compared to placebo 
(P<0.0001). The Phase III EXPAND trial 
(N=235) evaluated tezacaftor/ivacaftor 
and ivacaftor monotherapy in patients 
with one copy of the F508del mutation and 
one residual function mutation. Treatment 
with tezacaftor/ivacaftor resulted in 
mean absolute improvements of 6.8 and 
2.1 percentage points in ppFEV1 compared 
to placebo and ivacaftor monotherapy, 
respectively, from baseline to the average 
of the week four and eight measurements 
(P<0.0001). 
If approved, tezacaftor/ivacaftor 
may provide a more effective option for 
patients with specific combinations of 
F508del mutations. Tezacaftor/ivacaftor 
was granted the Breakthrough Therapy 
designation and Priority Review status by 
the FDA, with a decision expected by  
Feb. 28, 2018.
Ozanimod is an oral, selective 
sphingosine 1-phosphate receptor 
(S1PR) 1 and 5 modulator currently 
being investigated for the treatment of 
relapsing multiple sclerosis (RMS). 
The randomized, double-blind 
Phase III SUNBEAMTM (N=1,346) and 
RADIANCETM Part B (N=1,320) trials 
compared ozanimod (1 mg and 0.5 mg) 
orally once daily to Avonex® (interferon 
[IFN] beta-1a) intramuscularly once weekly 
for the treatment of RMS. In SUNBEAMTM, 
patients receiving ozanimod 1 mg and 
0.5 mg achieved a greater reduction in 
annualized relapse rate (ARR) compared to 
patients receiving IFN beta-1a (ARR=0.18, 
P<0.0001; ARR=0.24, P=0.0013; and 
ARR=0.35, respectively). In RADIANCETM 
Part B, patients receiving ozanimod 1 mg 
and 0.5 mg achieved a greater reduction 
in ARR compared to patients receiving IFN 
beta-1a (ARR=0.17, P<0.0001; ARR=0.22, 
P=0.0167; and ARR=0.28, respectively). In a 
pre-specified pooled analysis of both trials, 
treatment with ozanimod did not achieve 
statistical significance in the time to three-
month confirmed disability progression. 
Both trials reported no episodes of second 
or third degree atrioventricular block, 
similar infection rates between groups, 
and that most alanine aminotransferase 
increases that occurred were self-limiting.
If approved, ozanimod may provide 
an effective oral treatment option for RMS 
with a more favorable side effect profile 
than the currently available non-selective 
S1PR modulator. An NDA submission is 
anticipated by the end of 2017.
Patisiran, a small interfering 
ribonucleic acid (siRNA), targets a specific 
sequence of messenger RNA (mRNA) to 
reduce serum levels of transthyretin 
(TTR) protein. Patisiran is currently being 
studied for the treatment of hereditary 
amyloidogenic TTR (hATTR) amyloidosis. 
The Phase III APOLLO trial (N=225) 
compared patisiran to placebo in adults 
with hATTR amyloidosis and polyneuropathy. 
The primary endpoint was the between-
group difference in mean change in modified 
Neuropathy Impairment Score (mNIS+7) 
from baseline at 18 months. Patients 
receiving patisiran achieved a mean 6.0-
point reduction (improvement) in mNIS+7 
score from baseline at 18 months compared 
to a mean 28.0-point increase (worsening) 
with placebo (mean difference 34.0 points, 
P=9.26 x 10-24). Patients receiving patisiran 
achieved a mean 6.7-point reduction 
(improvement) in Norfolk-Quality of Life-
Diabetic Neuropathy score from baseline at 
18 months compared to a mean 14.4-point 
increase (worsening) with placebo (mean 
difference 21.1 points, P=1.10 x 10-10). 
Peripheral edema and infusion-related 
reactions occurred more frequently in the 
patisiran group than in the placebo group. 
If approved, patisiran will be the first 
RNA interference (RNAi) therapeutic, a 
new class of medications, and the first 
FDA-approved agent for the treatment of 
hATTR amyloidosis. The FDA has granted 
patisiran the Orphan Drug and Fast Track 
designations. A rolling NDA submission was 
initiated in November 2017.
NDA
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Ilaris® (canakinumab)
The Phase III CANTOS trial (N=10,061) compared 
canakinumab 300 mg, 150 mg, and 50 mg every three 
months to placebo in adults with a previous myocardial 
infarction (MI) and elevated high-sensitivity C-reactive 
protein. The incidence rate of nonfatal stroke, nonfatal 
MI, or cardiovascular (CV) death per 100-person years 
was 3.90, 3.86, and 4.11 for the canakinumab 300 mg, 
150 mg, and 50 mg groups, respectively, compared 
to 4.50 for the placebo group (P=0.031, P=0.021, and 
P=0.30, respectively). The incidence of CV death was 
not significantly lower for any of the canakinumab 
groups compared to placebo. A supplemental BLA 
submission is expected by the end of 2017.
Ocaliva® (obeticholic acid) 
The Phase IIb FLINT trial (N=283) compared treatment 
with obeticholic acid (OCA) 25 mg daily to placebo for 
72 weeks in patients with non-cirrhotic, non-alcoholic 
steatohepatitis (NASH). A greater proportion of patients 
treated with OCA achieved improved liver histology 
compared to the placebo group (45 versus 21 percent, 
P=0.0002). A retrospective analysis of the FLINT study 
found that 57 percent of patients with type 2 diabetes 
who were treated with OCA achieved improved liver 
histology (P<0.01). The Phase III pivotal REGENERATE 
trial is currently ongoing.
•  Treximet® (sumatriptan/naproxen) 
     2/2018
•  Factive® (gemifloxacin tablet) 
     3/2018
   
•  Sensipar® (cinacalcet tablet)
     3/2018 
•  Enbrel® (etanercept)
     4/2018    
 
•  Lexiva® (fosamprenavir tablet)  
     6/2018
     
•  Remodulin® (treprostinil injection)  
     6/2018
•  Acanya® (benzoyl peroxide/
     clindamycin phosphate 2.5%/1.2%) 
     7/2018 
•  Ampyra® (dalfampridine extended-
     release tablet ) 
     7/2018
 
Baricitinib
On April 14, 2017, Eli Lilly and Company 
and Incyte Corporation announced that the 
FDA issued a complete response letter (CRL) 
regarding the NDA for baricitinib, a Janus 
kinase (JAK) inhibitor being studied for the 
treatment of moderate-to-severe rheumatoid 
arthritis. The FDA requested additional data 
to determine the most appropriate doses and 
to characterize the risk-benefit profile given 
the thromboembolic events that occurred in 
clinical trials. The manufacturers announced 
in August 2017 that a new clinical trial would 
not be necessary. The NDA resubmission, 
which will include new safety and efficacy 
data, is planned for January 2018.   
DextenzaTM (dexamethasone insert)
On July 11, 2017, Ocular TherapeutixTM, Inc. 
announced that the FDA issued a second 
CRL for Dextenza TM (dexamethasone insert) 
for the intracanalicular treatment of ocular 
pain due to ophthalmic surgery. The CRL 
cited deficiencies in manufacturing and 
analytical testing. Citations from an FDA 
reinspection in May 2017 prompted the 
company to submit an amendment in July 
2017; however, the FDA did not review this 
information prior to issuing the CRL. The CRL 
indicated that resolution of the deficiencies 
is required before approval, but applicable 
sections of the amendment may be included 
in future submissions.
EvenityTM (romosozumab)
On July 16, 2017, Amgen and UCB announced 
that the FDA issued a CRL declining 
approval of Evenity™ (romosozumab), a 
subcutaneously-administered, bone-forming 
monoclonal antibody targeting sclerostin that 
is being investigated for the treatment of 
postmenopausal women with osteoporosis. 
Although no increased CV risk was observed 
in the FRAME clinical trial data that was 
included in the BLA, the FDA has requested 
data from the subsequent BRIDGE and ARCH 
trials after increased CV risk was observed in 
the ARCH trial. The manufacturers are pooling 
the requested data and plan to resubmit the 
BLA as an extension of the current review.
*Dates are estimates, current as of 12/1/17, and are subject to change due to any patent litigation or additional patents.
•  Aloxi® (palonosetron injection)  
     9/2018
•  Cialis® (tadalafil)  
     9/2018
 
• Staxyn® (vardenafil orally
      disintegrating tablet) 
  10/2018                                     
 
• Vesicare® (solifenacin 
      succinate) 
  10/2018
• Finacea® (azelaic acid gel) 
  11/2018
• Fortesta® (testosterone gel) 
  11/2018
• Lyrica® (pregabalin) 
  12/2018
•    Rapaflo® (silodosin)
       12/2018
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*Designates specialty drug.
HIV-1
RPE65-mediated 
inherited retinal 
dystrophy
Spark Therapeutics
Table Abbreviations: ADHD=attention-deficit hyperactivity disorder, 
BLA=Biologics License Application, HIV=human immunodeficiency virus, 
IV=intravenous, LGS=Lennox-Gastaut syndrome, NDA=New Drug Appli-
cation, PDUFA=Prescription Drug User Fee Act, PKU=phenylketonuria, 
SC=subcutaneous
LuxturnaTM (voretigene 
neparvovec) (subretinal)*
PDUFA date 1/12/2018
Neuroendocrine tumors
AndexXa® 
(andexanet alfa) (IV)
Factor Xa inhibitor 
antidote
Prevention of 
preterm birth
Burosumab (SC)* PDUFA date 4/17/2018
BAY94-9027 (IV)* Bayer Hemophilia A
Fremanezumab (SC)* Teva Pharmaceuticals Migraine prevention
Dasotraline ADHD NDA accepted 11/2017
Ibalizumab (IV)* Theratechnologies PDUFA date 4/3/2018
OlinvoTM (oliceridine) (IV)
LGS, Dravet syndrome NDA submitted 10/2017
Aerie 
Pharmaceuticals
Glaucoma, ocular 
hypertension
PDUFA date 2/28/2018
PDUFA date 2/12/2018
PDUFA date 1/27/2018
PDUFA date 2/2/2018
Multidrug-resistant 
HIV-1
Netarsudil (opthalmic)
Lutathera® (lutetium Lu 
177 dotatate) (IV)*
Gilead Sciences
PDUFA date 2/14/2018
Pegvaliase (SC)*
BioMarin 
Pharmaceuticals
PDUFA date 6/29/2018
BLA accepted 10/2017
BLA submitted 10/2017
Moderate-to-severe 
acute pain
NDA submitted 11/2017
Volanesorsen (SC)*
Familial 
chylomicronemia
 syndrome
PDUFA date 8/30/2018
Epidiolex® (cannabidiol)*
AbbVie Endometriosis NDA accepted 10/2017Elagolix 
GW Pharmaceuticals
Makena®  auto-injector 
(hydroxyprogesterone 
caproate) (SC) 
Bictegravir/emtricitabine/ 
tenofovir alafenamide
Advanced 
Accelerator 
Applications
AMAG 
Pharmaceuticals
Portola 
Pharmaceuticals
Ultragenyx, Kyowa 
Hakko Kirin    
X-linked 
hypophosphatemia
PKU
Akcea Therapeutics
Trevena
Sunovion 
Pharmaceuticals
Phase I:   37.9%
Phase II:  43.3%
Phase III: 18.8%
Agents in Clinical Development
Leading Indications with Agents 
in Late-Stage Development
1. Breast cancer
2. Non-small cell lung cancer
3. Colorectal cancer
4. Pancreatic cancer
5. Type 2 diabetes mellitus
6. Ovarian cancer
7. Alzheimer’s disease
8. Rheumatoid arthritis
9. Prostate cancer
10. Brain cancer
Phase III
Phas
e I
Ph
as
e 
II
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Who We Are and What We Do
The University of Massachusetts Medical School’s Clinical Pharmacy Services is a national leader in clinical 
pharmacy support. Established in 1999 to provide drug utilization review services for the Massachusetts 
Medicaid program, Clinical Pharmacy Services now provides clinical and operational support, consulting 
and service delivery in a broad range of areas such as evidence-based pharmaceutical care management, 
medication therapy management, patient-centered medical homes, pharmacy analytics, 
pharmacoeconomic analysis, and patient/prescriber outreach.  We have assembled a team with 
exceptional depth and experience in multiple fields. Our clients include state Medicaid agencies, pharmacy 
benefit managers  and  managed care plans. PIPELINE TRxENDS is produced annually to provide our clients 
with critical information about drugs in development.  
